Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 51: 1804-1810, 2005. First published August 4, 2005; 10.1373/clinchem.2005.049304
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2005.049304v1
51/10/1804    most recent
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Okada, M.
Right arrow Articles by Hama, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Okada, M.
Right arrow Articles by Hama, H.
Related Collections
Right arrow Lipids, Lipoproteins, and Cardiovascular Risk Factors
(Clinical Chemistry. 2005;51:1804-1810.)
© 2005 American Association for Clinical Chemistry, Inc.

Lipids, Lipoproteins, and Cardiovascular Risk Factors

Surfactant-Based Homogeneous Assay for the Measurement of Triglyceride Concentrations in VLDL and Intermediate-Density Lipoprotein

Masahiko Okada1,a, Tomohiro Saito2, Hajime Yoshimura2, Yasuhiko Noguchi2, Taeko Ito3, Hiroko Sasaki1 and Hitoshi Hama4

1 Division of Preventive Medicine, Graduate School of Medical and Dental Sciences, Niigata University, Niigata City, Japan.
2 Shino-Test Corporation, Sagamihara City, Japan.
3 Misono Hospital, Niigata City, Japan.
4 Kido Hospital, Niigata City, Japan.

aAddress correspondence to this author at: Division of Preventive Medicine, Graduate School of Medical and Dental Sciences, Niigata University, 1 Asahimachi, Niigata City 951-8510, Japan. Fax 025-223-0996; e-mail okadar{at}med.niigata-u.ac.jp.

Background: Existing studies have demonstrated the clinical significance of triglyceride content in VLDL (VLDL-TG) and intermediate-density lipoprotein (IDL-TG). We developed a homogeneous assay protocol to directly measure VLDL-TG.

Methods: Possible reagents and conditions for measuring VLDL-TG were comprehensively tested, and the "best" combination was determined. Healthy persons were instructed to consume a fatty meal after 15-h overnight fasting. Serum VLDL-TG + IDL-TG concentrations were measured using the proposed method. Patients with serum LDL-cholesterol concentrations ≥3.62 mmol/L (140 mg/dL) were administered simvastatin at a daily dose of 5 mg, and serum VLDL-TG concentrations were then measured.

Results: The combination of 2 nonionic surfactants played an important role in differentiating VLDL and IDL from other lipoproteins, probably via specific interactions with phospholipids and apolipoproteins. The regression line of the proposed method (y) and the ultracentrifugal assay (x) was: y = 0.98x + 0.31 mmol/L (r = 0.98; n = 73; P <0.05). The difference between postprandial total TG and VLDL-TG concentrations was statistically significant (P <0.05). After 8 weeks of therapy with simvastatin, total TG and LDL-cholesterol concentrations were 13.6% and 26.3% lower, respectively (P <0.05), whereas VLDL-TG did not show any significant decrease.

Conclusion: Our homogeneous method can measure TG content in VLDL and IDL.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Association for Clinical Chemistry.